KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Equity Average (2016 - 2025)

Historic Equity Average for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $18.2 billion.

  • Biogen's Equity Average rose 1024.77% to $18.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $18.2 billion, marking a year-over-year increase of 1024.77%. This contributed to the annual value of $17.5 billion for FY2025, which is 1097.05% up from last year.
  • Biogen's Equity Average amounted to $18.2 billion in Q4 2025, which was up 1024.77% from $17.9 billion recorded in Q3 2025.
  • In the past 5 years, Biogen's Equity Average registered a high of $18.2 billion during Q4 2025, and its lowest value of $10.7 billion during Q1 2021.
  • Over the past 5 years, Biogen's median Equity Average value was $14.3 billion (recorded in 2023), while the average stood at $14.1 billion.
  • As far as peak fluctuations go, Biogen's Equity Average crashed by 1749.38% in 2021, and later skyrocketed by 2251.99% in 2023.
  • Biogen's Equity Average (Quarter) stood at $10.9 billion in 2021, then increased by 19.75% to $13.1 billion in 2022, then grew by 11.94% to $14.6 billion in 2023, then increased by 12.96% to $16.5 billion in 2024, then rose by 10.25% to $18.2 billion in 2025.
  • Its Equity Average stands at $18.2 billion for Q4 2025, versus $17.9 billion for Q3 2025 and $17.3 billion for Q2 2025.